Yüksel Ürün: Immunotherapy Rechallenge in Metastatic Renal Cell Carcinoma / Bradley A. McGregor, cancer, Emre Yekedüz, Hatice Bölek, OncoDaily, Oncology, Rana

Yüksel Ürün: High Response in cSCC but Significant Rejection Risk With Checkpoint Drugs / Anh Kieu, Annabelle Wilson, Armando Teixeira-Pinto, Billie Bonevski,

Yüksel Ürün: ASCO LDP is One of ASCO’s Best / ASCO, ASCO LDP, cancer, Leadership Development Program, OncoDaily, Oncology, Yüksel Ürün

Yüksel Ürün: Three Words, One Mission / cancer, ESMO, ESMO 2025, ESMO 2025 Congress, ESMO2025, ESMO25, OncoDaily, Oncology, Yüksel Ürün

Yüksel Ürün: Ivonescimab + Chemo Improves PFS in 1L sq-NSCLC / cancer, Erika Hamilton, ESMO, ESMO 2025, ESMO 2025 Congress, ESMO2025, ESMO25, OncoDaily,

Yüksel Ürün: Global Cancer Burden Calls for Action on Prevention and Equity / cancer, OncoDaily, Oncology, Yüksel Ürün

Dr. Yüksel Ürün at VIRO 2025 shares insights on personalizing frontline kidney cancer treatment, emphasizing biology and patient-centered care.

Prof. Yüksel Ürün is a distinguished Professor of Medical Oncology at Ankara University School of Medicine and one of Turkey’s leading experts in

Yüksel Ürün: Liquid Biopsy Is No Longer the Future / Antonio Alcaraz, Benjamin L Maughan, cancer, Emmanuel S Antonarakis, genitourinary malignancies, Lars

Yüksel Ürün: Cancer Prevention is the Quiet Revolution / cancer, Cancer Prevention, Cancer research, OncoDaily, Oncology, Yüksel Ürün

Yüksel Ürün: Science Is Better When It’s Shared / cancer, Headlines, OncoDaily, Oncology, Yüksel Ürün

Yüksel Ürün: Breast Cancer Care Shouldn’t Be a Luxury / Amal Arahmani, Ander Urruticoechea, Ankara University School of Medicine, Barbro Lindholm, Boon H.

Yüksel Ürün: A Promising Option for Non–Clear-Cell Renal Cell Carcinoma / cancer, Craig Gedye, Cristina Suárez, David Pook, Erhan Gokmen, european urology,

Yüksel Ürün: How Should We Treat mCRPC and HRR Deficiency? / Ankara University School of Medicine, cancer, HRR Deficiency, mCRPC, metastatic

Paolo Tarantino: First Positive Phase 3 Trial for a Bispecific ADC / ADCs, Biokin Pharma, BMS, cancer, Minhua Chu, OncoDaily, Oncology, Paolo Tarantino,

Preclinical and observational studies suggest that exercise may improve cancer outcomes. However, definitive level 1 evidence is lacking. In this phase 3, randomized trial conducted at 55 centers, ...

This cross-sectional study evaluated the changes in the proportion of US adults who were unaware they had hypertension, diabetes, or a high cholesterol level using 2013 to 2023 data from the National ...